Abstract
OBJECTIVES--To establish, in a double blind manner, the antiparkinsonian effects of repeated dosing with entacapone, a peripheral COMT inhibitor. METHODS--A one month, cross over study was conducted. During the two four-week treatment periods, entacapone (200 mg) or placebo was given with each levodopa dose four to 10 times daily. Motor responses were repeatedly quantified using the motor part of UPDRS. Plasma levodopa and its metabolites were measured. RESULTS--Entacapone prolonged the availability of levodopa in the plasma and thus to the brain by decreasing its peripheral O-methylation and slowing its elimination rate, without affecting the maximum plasma levodopa concentration or the time to maximum concentration. Corresponding with the pharmacokinetic findings, entacapone prolonged the duration of motor response to an individual levodopa/DDC inhibitor dose by 34 minutes (24%, P = 0.001) and dyskinesiae by 39 minutes (37%, P = 0.002) compared with placebo, without affecting their magnitude or starting time. Entacapone treatment resulted in a reduction of 16% in the mean total daily levodopa dose due to dyskinesiae. Also, according to the home diaries, the mean daily "on" time increased by 2.1 hours compared with placebo, despite the lowered mean levodopa intake. CONCLUSION--The efficacy of repeated entacapone dosing as an adjuvant to levodopa/DDC inhibitor treatment for Parkinson's disease with levodopa related fluctuations is verified.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Esteguy M., Bonnet A. M., Kefalos J., Lhermitte F., Agid Y. Le test à la L-Dopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985;141(5):413–415. [PubMed] [Google Scholar]
- Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
- Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994 Jan;44(1):77–80. doi: 10.1212/wnl.44.1.77. [DOI] [PubMed] [Google Scholar]
- Kuruma I., Bartholini G., Tissot R., Pletscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther. 1971 Jul-Aug;12(4):678–682. doi: 10.1002/cpt1971124678. [DOI] [PubMed] [Google Scholar]
- Merello M., Lees A. J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186–189. doi: 10.1136/jnnp.57.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Myllylä V. V., Sotaniemi K. A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 1993;45(5):419–423. doi: 10.1007/BF00315512. [DOI] [PubMed] [Google Scholar]
- Männistö P. T., Tuomainen P., Tuominen R. K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol. 1992 Mar;105(3):569–574. doi: 10.1111/j.1476-5381.1992.tb09020.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nissinen E., Lindén I. B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262–266. doi: 10.1007/BF00173538. [DOI] [PubMed] [Google Scholar]
- Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
- Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal. 1991;9(2):167–176. doi: 10.1016/0731-7085(91)80140-5. [DOI] [PubMed] [Google Scholar]